Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
-
Published:2021-05-27
Issue:7
Volume:26
Page:1237-1237
-
ISSN:1341-9625
-
Container-title:International Journal of Clinical Oncology
-
language:en
-
Short-container-title:Int J Clin Oncol
Author:
Aogi KenjiroORCID,
Watanabe Kenichi,
Kitada Masahiro,
Sangai Takafumi,
Ohtani Shoichiro,
Aruga Tomoyuki,
Kawagichi Hidetoshi,
Fujisawa Tomomi,
Maeda Shigeto,
Morimoto Takashi,
Sato Nobuaki,
Takao Shintaro,
Morita Satoshi,
Masuda Norikazu,
Toi Masakazu,
Ohno Shinji
Abstract
In the original publication, the name of the fourth author should be: Takafumi Sangai and his affiliation should be.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery